Fig. 1: B cell characterization in acute COVID-19 infection by high-dimensional FCM.
From: Extrafollicular B cell responses correlate with neutralizing antibodies and morbidity in COVID-19
a–f, PBMCs from HD (n = 17), OUT-C (n = 7) or ICU-C (n = 10) patients were analyzed by FCM. Representative patient samples were selected for display (OUT-C: day 4 after symptom onset; ICU-C: day 7 after symptom onset). a, Primary population gating of representative patient samples. b, ASC sub-gating (CD138+ ASC and CD138− ASC) of representative patient samples. c, Transitional B cell sub-gating (CD21lo Tr and CD21hi Tr) of representative patient samples. d, Double-negative B cell sub-gating (DN1, DN2 and DN3) of representative patient samples. e, Naive B cell sub-gating (resting naive (rN) and aN) of representative patient samples. f, Memory B cell sub-gating (mM, usM, dM and sM) of representative patient samples displayed a decrease in usM in ICU-C. dM, IgD-only memory; mM, IgM-only memory; usM, unswitched memory.
